C
CORE BiomedicineBiotech
CORE Biomedicine develops biotech solutions for disease treatment and research applications.
$21MSeries A
Investor undisclosed
A $21M Series A for a biotech company in 2026 suggests the market is still funding platform plays in drug discovery/research tools, but the relatively modest check size hints investors are being selective—likely betting on CORE's specific technical moat rather than category tailwinds. If you're building in adjacent biotech infrastructure (lab automation, data platforms, regulatory software), this signals that generalist capital is still available, but you'll need a defensible technical angle, not just a problem statement.